Welcome to CureTech 


CureTech Ltd. is a biotechnology company developing novel, broad-spectrum, immune modulating products for the treatment and control of cancer. 

Building on the broad experience of our team, we have advanced our lead antibody, pidilizumab (CT-011), into late stage clinical testing in a number of oncology indications. Our products are antibodies and peptide-based vaccines designed to modulate the immune response allowing it to exert its anti-cancer activity in an effective manner.

A licensing agreement for further development of pidilizumab has been signed with Medivation (Nasdaq: MDVN) in late 2014. Overall deal value is $360MM plus staged royalties on sales.

Our Products

 

The company’s products are antibodies and peptide-therapeutics designed to modulate the immune response allowing it to exert its anti-cancer activity in an effective manner.

Our lead product, pidilizumab (CT-011), is a humanized monoclonal antibody that exhibits efficient anti-cancer immune response against a wide variety of mouse and human tumor models. Pidilizumab which is being developed as a treatment for hematological malignancies and solid tumors has demonstrated robust and durable responses in patients with DLBCL (ORR: 45%; CR 37.5% and PR 7.5%) and follicular lymphoma (ORR: 66%; CR 52% and PR 14%). Notably, Pidilizumab was found active in diffuse intrinsic pontine glioma (DIPG), the most devastating childhood brain cancer, where 3 out of 9 patients have exhibited durable clinical benefit and median overall survival was dramatically extended to 16.5 months well over the expected 9.3 months for this group of patients.  Modest activity has also been noted in multiple myeloma, colorectal cancer and melanoma.